UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 239

Sortiert nach

Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?

Cancer research (Chicago, Ill.), 2021-09, Vol.81 (17), p.4385-4393

2021

Link zum Volltext

Verfügbarkeit prüfen

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

The New England journal of medicine, 2014-09, Vol.371 (11), p.1028-1038

2014

Link zum Volltext

Verfügbarkeit prüfen

Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.257-266

2012

Link zum Volltext

Verfügbarkeit prüfen

Concise Review: Mesenchymal Stem Cell‐Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise

Stem cells translational medicine, 2018-09, Vol.7 (9), p.651-663

2018

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

Nature medicine, 2023-04, Vol.29 (4), p.888-897

2023

Link zum Volltext

Verfügbarkeit prüfen

Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics

Molecules (Basel, Switzerland), 2021-12, Vol.26 (24), p.7469

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2010-03, Vol.28 (9), p.1496-1501

2010

Link zum Volltext

Verfügbarkeit prüfen

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment

Endocrine-related cancer, 2013-10, Vol.20 (5), p.R269-R290

2013

Link zum Volltext

Verfügbarkeit prüfen

Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer

Journal of clinical oncology, 2024-03, Vol.42 (7), p.852

Denmeade, Samuel R

2024

Link zum Volltext

Verfügbarkeit prüfen

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

The Journal of clinical investigation, 2022-12, Vol.132 (23)

2022

Link zum Volltext

Verfügbarkeit prüfen

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Nature communications, 2024-01, Vol.15 (1), p.14-14, Article 14

2024

Link zum Volltext

Verfügbarkeit prüfen

Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer

The Prostate, 2023-11, Vol.83 (15), p.1470-1493

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin

Molecular cancer therapeutics, 2009-05, Vol.8 (5), p.1378-1386

2009

Link zum Volltext

Verfügbarkeit prüfen

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

Science translational medicine, 2012-06, Vol.4 (140), p.140ra86

2012

Link zum Volltext

Verfügbarkeit prüfen

The SERCA pump as a therapeutic target: Making a "smart bomb" for prostate cancer

Cancer biology & therapy, 2005-01, Vol.4 (1), p.21-29

2005

Link zum Volltext

Verfügbarkeit prüfen

Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer

Oncotarget, 2013-01, Vol.4 (1), p.106-117

2013

Link zum Volltext

Verfügbarkeit prüfen

The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin

PloS one, 2007-09, Vol.2 (9), p.e844-e844

2007

Link zum Volltext

Verfügbarkeit prüfen

Knockin of mutant PIK3CA activates multiple oncogenic pathways

Proceedings of the National Academy of Sciences - PNAS, 2009-02, Vol.106 (8), p.2835-2840

2009

Link zum Volltext

Verfügbarkeit prüfen

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2149-2156

2017

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)

Cancer biology & therapy, 2008-06, Vol.7 (6), p.974-982

2008

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers

Clinical cancer research, 2006-07, Vol.12 (13), p.4072-4079

2006

Link zum Volltext

Verfügbarkeit prüfen

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss

European urology open science (Online), 2022-07, Vol.41, p.112-115

2022

Link zum Volltext

Verfügbarkeit prüfen

First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer

The Prostate, 2023-09, Vol.83 (12), p.1127-1132

2023

Link zum Volltext

Verfügbarkeit prüfen

The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications

Nature reviews. Urology, 2023-05, Vol.20 (5), p.265-278

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 239

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(225)
Mit Volltextzugriff
(221)

Publikationsform

Artikel
(235)
Buchkapitel
(2)
Berichte
(1)
Texte
(1)

Sprache

Englisch
(239)
Japanisch
(20)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy

Concise Review: Mesenchymal Stem Cell‐Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment

Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer

Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

The SERCA pump as a therapeutic target: Making a "smart bomb" for prostate cancer

Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer

The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin

Knockin of mutant PIK3CA activates multiple oncogenic pathways

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)

Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss

First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer

The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial

Suchergebnisse filtern